Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

IC14 in Adult Patients With Dengue Fever

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03875560
Recruitment Status : Withdrawn (seeking funding)
First Posted : March 14, 2019
Last Update Posted : March 14, 2019
Sponsor:
Information provided by (Responsible Party):
Implicit Bioscience

Brief Summary:
Randomized, double-blind, placebo-controlled, safety, PK/PD and preliminary efficacy study of intravenous IC14 in adult patients in a dengue-endemic region presenting with fever > 38°C for < 48 hours with a positive NS1 strip assay or reverse-transcriptase polymerase chain reaction assay for dengue virus.

Condition or disease Intervention/treatment Phase
Dengue Fever Biological: IC14 Drug: Placebo Phase 2

Detailed Description:

The study will be conducted in two parts and will include an open label phase of a single dose of IC14 (Part A) and a randomized phase of multiple doses of IC14 and placebo (Part B). Up to 52 patients will be enrolled in both parts of the study.

Part A will consist of 12 patients given one of three doses of IC14 as a single dose open-label . Each patient must complete 14 days before the enrollment of subsequent patients. Part A subjects will be hospitalized for 4 days. During and at the end of 4-day admission to the clinical research unit, and on Study Days 5, 6, 7, 14, 21 and 32, Part A patients will have their health status assessed. The last subject in Part A must complete 32 days of participation before Part B of the trial is opened.

Part B consists of 40 patients randomized equally to one of 4 dosing regimens which will include a single dose or multiple doses of IC14 or placebo given at different dosing frequencies. In Part B, Cohort 1 and 2 subjects (single dose) will be inpatient for 4 days and Cohort 3 and 4 subjects (four daily doses) will be inpatient for 5 days. During and at the end of the admission to the clinical research unit, and on Study Days 5, 6, 7, 14, 21 and 32, Part B patients will have their health status assessed.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Safety, Pharmacokinetic, Pharmacodynamic and Preliminary Efficacy Study of IC14 in Adult Patients With Dengue Fever
Estimated Study Start Date : May 2019
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dengue Fever

Arm Intervention/treatment
Experimental: Part A/Single Dose
IC14 0.5, 1.0 or 2.0 mg/kg IV as a single dose (subjects are assigned and not randomized to this arm. When Part A is complete, Enrollment to Part B will commence).
Biological: IC14
recombinant chimeric anti-human CD14 monoclonal antibody

Experimental: Part B/Cohort 1
IC14 4 mg/kg/day IV or placebo IV x 1 day.
Biological: IC14
recombinant chimeric anti-human CD14 monoclonal antibody

Drug: Placebo
Inactive

Experimental: Part B/Cohort 2
IC14 8 mg/kg/day IV or placebo IV x 1 day.
Biological: IC14
recombinant chimeric anti-human CD14 monoclonal antibody

Drug: Placebo
Inactive

Experimental: Part B/Cohort 3
IC14 2 mg/kg/day IV x 1 day followed by IC14 1 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
Biological: IC14
recombinant chimeric anti-human CD14 monoclonal antibody

Drug: Placebo
Inactive

Experimental: Part B/Cohort 4
IC14 4 mg/kg/day IV x 1 day followed by IC14 2 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
Biological: IC14
recombinant chimeric anti-human CD14 monoclonal antibody

Drug: Placebo
Inactive




Primary Outcome Measures :
  1. Incidence of treatment-emergent adverse events (safety, tolerability) [ Time Frame: 32 days ]
    Number of patients with treatment-related adverse events as classified according to MedDRA

  2. Area under the curve of IC14 serum concentration [ Time Frame: 14 days ]
    Area under the curve of IC14 serum concentration


Secondary Outcome Measures :
  1. Dengue viral load [ Time Frame: 32 days ]
    Impact of treatment on dengue viral load measured by quantitative viral load and plasma NS1 viral protein

  2. Fever [ Time Frame: 32 days ]
    Impact of treatment on duration of fever

  3. Dengue symptom score [ Time Frame: 32 days ]
    Impact of treatment on dengue symptom severity (0 normal] to 24 [worst])

  4. Disease severity [ Time Frame: 32 days ]
    Impact of treatment on duration of hospitalization; incidence and duration of intensive care unit admission; and incidence of progression to dengue with warning signs or severe dengue

  5. Mortality [ Time Frame: 32 days ]
    Impact of treatment on survival



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Fever > 38°C for < 48 hours and clinical presentation consistent with dengue fever.
  • Positive NS1 strip assay or reverse-transcriptase polymerase chain reaction (RT-PCR) assay for dengue virus.
  • Informed consent form signed and dated by the patient.
  • Subject able to give informed consent and able to comply with all study visits and all study procedures.
  • Females of childbearing potential should be using and committed to continue using acceptable birth control methods.

    • Sexual abstinence (inactivity) for 1 month prior to screening through study completion; or
    • Intrauterine device (IUD) in place for at least 3 months prior to study through study completion; or
    • Stable hormonal contraception for at least 3 months prior to study through study completion; or
    • Surgical sterilization (vasectomy) of male partner at least 6 months prior to study.
  • To be considered of non-childbearing potential, females should be surgically sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be post-menopausal and at least 3 years since last menses.

Exclusion Criteria

  • One or more of the following dengue warning signs and symptoms:

    • Intense and continuous abdominal pain (referred pain or on palpation);
    • Persistent vomiting;
    • Fluid accumulation (ascites, pleural effusion, or pericardial effusion);
    • Postural hypotension and/or collapse;
    • Painful hepatomegaly > two centimeters below the right costal margin;
    • Mucosal bleeding;
    • Major bleeding (hematemesis and/or melena);
    • Lethargy and/or irritability;
    • Diminished urine output;
    • Hypothermia;
    • Progressive increase in hematocrit or 20% above baseline or normal for age;
    • Abrupt drop in platelets;
    • Respiratory discomfort.
  • One or more of the following signs and symptoms of severe dengue, such as:

    • Severe plasma extravasation, leading to shock evidenced by one or more of the following:
    • Tachycardia;
    • Cold distal extremities;
    • Weak, thready pulse;
    • Slow capillary refill (> 2 seconds);
    • Pulse pressure < 20 mmHg;
    • Tachypnea; or
    • Oliguria (<1.5 mL/kg/hr).
    • Systolic blood pressure < 90 mmHg or decrease >40 mmHg;
    • Cyanosis;
    • Fluid accumulation with respiratory discomfort;
    • Severe bleeding; or
    • Severe organ impairment, evidenced by one or more of the following:
    • Liver impairment (AST >1000 U/L, international normalized ratio >1.5);
    • Renal impairment (serum creatinine ≥1.5 mg/dL); or
    • Myocarditis, pericarditis, or clinical heart failure (by chest x-ray, echocardiography, electrocardiogram, or cardiac enzymes if available).
  • Female who is pregnant, lactating or of childbearing potential.
  • Self-reported or suspected congenital or acquired immunodeficiency (including HIV infection); or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the previous 3 months).
  • Prior vaccination against dengue fever.
  • Significant chronic illness that, in the opinion of the Investigator, would interfere with study validity, conduct or completion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03875560


Sponsors and Collaborators
Implicit Bioscience
Investigators
Layout table for investigator information
Study Director: Jan Agosti, MD Implicit Bioscience

Layout table for additonal information
Responsible Party: Implicit Bioscience
ClinicalTrials.gov Identifier: NCT03875560     History of Changes
Other Study ID Numbers: EDF-01
First Posted: March 14, 2019    Key Record Dates
Last Update Posted: March 14, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Fever
Dengue
Body Temperature Changes
Signs and Symptoms
Arbovirus Infections
Virus Diseases
Flavivirus Infections
Flaviviridae Infections
RNA Virus Infections
Hemorrhagic Fevers, Viral